Kairos Pharma, Ltd. (KAPA)
KAPA moved a median of -1.45% 30 minutes after news, and -2.86% by the close. How KAPA actually reacts to news — the realized, point-in-time move the market made, measured across 140 labeled events over the last three years with zero look-ahead.
KAPA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -1.06% | 23% | 129 |
| 30-min | -1.45% | 35% | 136 |
| 60-min | -2.00% | 36% | 136 |
| to close | -2.86% | 32% | 136 |
| Middle 50% of KAPA reactions | -5.16% to +1.38% |
|---|---|
| Median reaction (30-min) | -1.45% |
| Measured reactions | 140 |
Half of all Kairos Pharma, Ltd. news events land between -5.16% and +1.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when KAPA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KAPA's baseline. Nothing else.
Recent KAPA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Kairos Pharma, LTD. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | -27.67% | |
| Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer | Press release | Business Wire | -1.89% | -27.67% | |
| Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA | Press release | Business Wire | +0.00% | -1.14% | |
| Form 8-K Kairos Pharma, LTD. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.35% | |
| Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | Business Wire | +0.00% | -5.68% | |
| Form 8-K Kairos Pharma, LTD. For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -12.69% | -9.97% | |
| Kairos Pharma Announces 1-for-7 Reverse Stock Split | Press release | Business Wire | -12.69% | -9.97% | |
| Form 10-Q Kairos Pharma, LTD. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.06% | +1.52% | |
| Form 8-K Kairos Pharma, LTD. For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -13.13% | -17.71% | |
| Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer | Press release | Business Wire | -13.13% | -17.71% | |
| Form 8-K Kairos Pharma, LTD. For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | -2.28% | -7.10% | |
| Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market | Press release | Business Wire | -2.28% | -7.10% | |
| Form 8-K Kairos Pharma, LTD. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -4.07% | |
| Form 8-K Kairos Pharma, LTD. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -8.15% | -5.32% | |
| Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders | Press release | Business Wire | -8.15% | -5.32% | |
| Form DEFA14A Kairos Pharma, LTD. | SEC filing · Form DEFA14A | SEC EDGAR | — | +1.69% | |
| Form ARS Kairos Pharma, LTD. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -3.57% | -7.64% | |
| Form DEF 14A Kairos Pharma, LTD. For: May 22 | SEC filing · Form DEF | SEC EDGAR | -3.57% | -7.64% | |
| Form 8-K Kairos Pharma, LTD. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.83% | |
| Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award | Press release | Business Wire | +1.91% | +4.52% | |
| Form 10-Q Kairos Pharma, LTD. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.91% | +4.52% | |
| Form PRE 14A Kairos Pharma, LTD. For: May 11 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +0.38% | |
| Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings | Press release | Business Wire | -1.15% | -4.75% | |
| Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation | Press release | Business Wire | — | -0.35% | |
| Form 10-K Kairos Pharma, LTD. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.07% | +4.84% | |
| Form 8-K Kairos Pharma, LTD. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | +6.83% | |
| Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics | Press release | Business Wire | +2.05% | +6.83% | |
| Form 8-K Kairos Pharma, LTD. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -5.15% | -23.98% | |
| Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics | Press release | Business Wire | -5.15% | -23.98% | |
| Form EFFECT Kairos Pharma, LTD. | SEC filing · Form EFFECT | SEC EDGAR | -1.76% | -6.93% | |
| Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference | Press release | Business Wire | +1.68% | +4.14% | |
| Form S-3 Kairos Pharma, LTD. | SEC filing · Form S-3 | SEC EDGAR | -4.44% | -7.58% | |
| Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer | Press release | Business Wire | +0.00% | -1.42% | |
| Form 10-Q Kairos Pharma, LTD. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.28% | +3.34% | |
| Kairos Pharma Provides Shareholder Update | Press release | Business Wire | -1.99% | -13.26% | |
| Form 8-K Kairos Pharma, LTD. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | +0.00% | |
| Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting | Press release | Business Wire | -2.49% | -2.50% | |
| Form 8-K Kairos Pharma, LTD. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | -6.40% | |
| Form 8-K Kairos Pharma, LTD. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -5.26% | -8.27% | |
| Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 | Press release | Business Wire | -5.26% | -8.27% | |
| Form 8-K Kairos Pharma, LTD. For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | -4.58% | +2.29% | |
| Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year | Press release | Business Wire | -4.58% | +2.29% | |
| Form 8-K Kairos Pharma, LTD. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | -2.70% | |
| Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer | Press release | Business Wire | -1.89% | -2.70% | |
| Form 8-K Kairos Pharma, LTD. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -2.76% | +0.69% | |
| Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025 | Press release | Business Wire | -2.76% | +0.69% | |
| Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | Business Wire | -2.76% | +0.69% | |
| Form 10-Q Kairos Pharma, LTD. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 10-K/A Kairos Pharma, LTD. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.90% | +0.95% | |
| Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 | Press release | Business Wire | -0.92% | +1.87% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KAPA section they belong to.
Where else KAPA is measured.
KAPA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kairos Pharma, Ltd.'s median reaction calculated?
Every labeled KAPA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 140 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of KAPA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KAPA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.